株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

先端巨大症:パイプライン製品の分析

Acromegaly - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 192431
出版日 ページ情報 英文 91 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
先端巨大症:パイプライン製品の分析 Acromegaly - Pipeline Review, H2 2016
出版日: 2016年09月21日 ページ情報: 英文 91 Pages
概要

先端巨大症は、成人期に下垂体で成長ホルモンが過剰に生成される場合に発症するホルモン障害です。体臭、疲れやすい、頭痛、巨大な足、過剰な身長、関節周囲の骨の部位の腫れ、歯の間隔が広い、睡眠時無呼吸などの症状が見られます。治療には、外科手術、ドーパミン作動薬、成長ホルモン拮抗薬などが含まれます。

当レポートでは、先端巨大症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

先端巨大症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Aegis Therapeutics, LLC
  • Antisense Therapeutics Limited
  • Chiasma, Inc.
  • Crinetics Pharmaceuticals, Inc.
  • DexTech Medical AB
  • Foresee Pharmaceuticals, LLC
  • Glide Pharmaceutical Technologies Limited
  • Ionis Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Italfarmaco S.p.A.
  • Novartis AG
  • Peptron, Inc.
  • Sompharmaceuticals S.A.
  • Strongbridge Biopharma plc

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ATL-1103
  • BIM-23A758
  • COR-005
  • FP-002
  • G-02113
  • ISIS-GHRLRx
  • ITF-2984
  • L-779976
  • octreotide acetate
  • octreotide acetate
  • octreotide acetate
  • octreotide acetate long acting
  • octreotide acetate SR
  • octreotide SR
  • pasireotide ER
  • Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors
  • Somadex
  • SXN-101742
  • SXN-101959

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8480IDB

Summary

Global Markets Direct's, 'Acromegaly - Pipeline Review, H2 2016', provides an overview of the Acromegaly pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acromegaly
  • The report reviews pipeline therapeutics for Acromegaly by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acromegaly therapeutics and enlists all their major and minor projects
  • The report assesses Acromegaly therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acromegaly

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acromegaly
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acromegaly Overview
  • Therapeutics Development
    • Pipeline Products for Acromegaly - Overview
    • Pipeline Products for Acromegaly - Comparative Analysis
  • Acromegaly - Therapeutics under Development by Companies
  • Acromegaly - Therapeutics under Investigation by Universities/Institutes
  • Acromegaly - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Acromegaly - Products under Development by Companies
  • Acromegaly - Products under Investigation by Universities/Institutes
  • Acromegaly - Companies Involved in Therapeutics Development
    • Aegis Therapeutics, LLC
    • Amryt Pharma plc
    • Antisense Therapeutics Limited
    • Chiasma, Inc.
    • Crinetics Pharmaceuticals, Inc.
    • DexTech Medical AB
    • Foresee Pharmaceuticals, LLC
    • Glide Pharmaceutical Technologies Limited
    • Ionis Pharmaceuticals, Inc.
    • Ipsen S.A.
    • Italfarmaco S.p.A.
    • Midatech Pharma Plc
    • Novartis AG
    • Peptron, Inc.
    • Strongbridge Biopharma plc
    • Sun Pharma Advanced Research Company Ltd.
  • Acromegaly - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • atesidorsen sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • COR-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FP-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IONIS-GHRLRx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ITF-2984 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-779976 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate long acting - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Somadex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SXN-101959 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Acromegaly - Dormant Projects
  • Acromegaly - Discontinued Products
  • Acromegaly - Product Development Milestones
    • Featured News & Press Releases
      • Jul 27, 2016: Positive Results Achieved from Interim Analysis of ATL1103 Higher Dose Study
      • Jul 13, 2016: ATL1103 Patent Update
      • Jun 28, 2016: Glide Technologies announces successful clinical proof-of-concept study
      • Jun 14, 2016: Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa
      • Jun 01, 2016: Antisense provides update on ATL1103 clinical trials
      • May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology
      • May 19, 2016: Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI
      • May 12, 2016: Orphan Drug designation from FDA for ATL1103 in Acromegaly
      • Apr 26, 2016: Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide
      • Apr 18, 2016: Chiasma Provides Update Regarding FDA's Complete Response Letter for Mycapssa New Drug Application
      • Apr 15, 2016: FDA Issues Complete Response Letter for Mycapssa New Drug Application
      • Mar 14, 2016: Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly
      • Nov 03, 2015: Strongbridge Biopharma Announces Data Presentation at the Society for Endocrinology BES 2015 Conference
      • Sep 09, 2015: ATL1103 Higher Dose Study-Dosing Commenced
      • Aug 17, 2015: Chiasma Announces FDA Acceptance For Filing of New Drug Application for Octreotide Capsules in Acromegaly
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acromegaly, H2 2016
  • Number of Products under Development for Acromegaly - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Acromegaly - Pipeline by Aegis Therapeutics, LLC, H2 2016
  • Acromegaly - Pipeline by Amryt Pharma plc, H2 2016
  • Acromegaly - Pipeline by Antisense Therapeutics Limited, H2 2016
  • Acromegaly - Pipeline by Chiasma, Inc., H2 2016
  • Acromegaly - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016
  • Acromegaly - Pipeline by DexTech Medical AB, H2 2016
  • Acromegaly - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016
  • Acromegaly - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016
  • Acromegaly - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
  • Acromegaly - Pipeline by Ipsen S.A., H2 2016
  • Acromegaly - Pipeline by Italfarmaco S.p.A., H2 2016
  • Acromegaly - Pipeline by Midatech Pharma Plc, H2 2016
  • Acromegaly - Pipeline by Novartis AG, H2 2016
  • Acromegaly - Pipeline by Peptron, Inc., H2 2016
  • Acromegaly - Pipeline by Strongbridge Biopharma plc , H2 2016
  • Acromegaly - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Acromegaly - Dormant Projects, H2 2016
  • Acromegaly - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Acromegaly, H2 2016
  • Number of Products under Development for Acromegaly - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top